Harvey Fineberg, Institute of Medicine, Washington
In his talk, Harvey Fineberg describes a recent fundamental shift in US policy on dual use research on microbes: In the past, the burden of proof whether research or the publication of research results was too high a risk, lay with the regulating body, i.e. mainly the government. The halting of funding turned this around. Now the researchers and the research institutions have the burden of proof to show that the benefits of going forward with their research outweigh the risks. Fineberg describes what a discussion about this kind of risk-benefit analysis could look like and who needs to be involved.